Lyell Immunopharma announces $80 million private placement
LYEL•Lyell Immunopharma agreed to raise approximately $80 million by selling 7,428,040 shares at $10.77 each. The financing is expected to extend its cash runway into 2028.
LYEL•LYEL•LYEL•Lyell Immunopharma agreed to raise approximately $80 million by selling 7,428,040 shares at $10.77 each. The financing is expected to extend its cash runway into 2028.
Lyell Immunopharma agreed to sell 7,428,040 shares of common stock at $10.77 per share, matching the November 3, 2026 closing price, for approximately $80 million in gross proceeds. Closing is expected on or about November 4, subject to customary conditions. Net proceeds will support ronde-cel trials and regulatory submissions, LYL273 development and general corporate purposes. The financing is expected to extend the company’s cash runway into 2028, beyond ronde-cel’s planned BLA submission in the second half of 2027.
